TGR-1202, a next generation PI3K-delta inhibitor in CLL and B-cell lymphomas

TGR-1202, a next generation PI3K-delta inhibitor in CLL and B-cell lymphomas

VJHemOnc

4 years
280 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Owen A O'Connor, MD, PhD from the Columbia University Medical Center Center for Lymphoid Malignancies, New York, NY, talks about a study on TGR-1202 presented at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL. TGR-1202 is a novel, next generation PI3K-delta inhibitor, found to show a favorable safety and tolerability profile and promising activity in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL.
Up Next Autoplay